Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Peking University First Hospital | OTHER |
| Beijing Hospital | OTHER_GOV |
Not provided
Not provided
Not provided
Not provided
Retrospective and Prospective single arm, observational study to evaluate efficacy and safety of NIF in the treatment of ventricular tachycardia and ventricular fibrillation. The information registration of the target population will be collected with the hospital HIS system or LIS system.
Subjects enrolled in the retrospective study may be enrolled in a prospective study if the study drug is re-used, but in the end only the most-registered case of the subject would be collected.
The recommended treatment plan for this study is from the usage and dosage of NIF. The clinician can make appropriate adjustments to the specific usage and dosage according to the patient's condition.
Load dose: Adults usually use 0.3mg/kg each time, under continuous ECG monitoring, the injection should be completed within 5 minutes, and the maximum dose should not exceed 0.5 mg/kg.
Maintenance dose: After load injection, the adult routine dose is 0.4 mg/kg/h under continuous ECG monitoring. The dosage could be appropriately increased or decreased according to the patient's reaction, but the maximum dose should not exceed 0.8 mg/kg/h.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Nifekalant hydrochloride | Drug | Treatment is not limited. Patients who have used or will use Nifekalant hydrochloride. |
|
| Measure | Description | Time Frame |
|---|---|---|
| The rate of termination / prevention of ventricular tachycardia / ventricular fibrillation attack and relapse. | The efficiency during the treatment and observation periods, including the rate of termination / prevention of ventricular tachycardia / ventricular fibrillation attack and relapse. | From the beginning of the administration to 48 hours after the end of the administration. |
| Measure | Description | Time Frame |
|---|---|---|
| Number of Participants with adverse events | Number of Participants with Tdp, ventricular tachycardia or ventricular fibrillation. | From the beginning of the administration to 48 hours after the end of the administration. |
| Heart rate |
Not provided
Inclusion Criteria:
Exclusion Criteria:
-
Not provided
Not provided
Not provided
Not provided
Patients with life-threatening ventricular tachycardia or ventricular fibrillation in cases where other drugs are ineffective or inoperable.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Jing Xiong | Contact | +86-028-85320612 | xiongjing@baili-pharm.com |
| Name | Affiliation | Role |
|---|---|---|
| Yong Huo | Peking University First Hospital | Principal Investigator |
| Jing Zhou | Peking University First Hospital | Principal Investigator |
| Min Yi Cui |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Peking University First Hospital | Recruiting | Beijing | Beijing Municipality | 100000 | China |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D017180 | Tachycardia, Ventricular |
| D014693 | Ventricular Fibrillation |
| ID | Term |
|---|---|
| D013610 | Tachycardia |
| D001145 | Arrhythmias, Cardiac |
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C076259 | nifekalant |
| D007267 | Injections |
| ID | Term |
|---|---|
| D004333 | Drug Administration Routes |
| D004358 | Drug Therapy |
| D013812 | Therapeutics |
Not provided
Not provided
Not provided
Not provided
Not provided
The subjects' heart rate will be recorded and the abnormalities will be analyzed.
| 3 days before the beginning of the administration to 48 hours after the end of the administration. |
| The survival rate | The 30 days survival rate. | 30 days after the end of administration. |
| Blood pressure | Both systolic and diastolic pressures will be assessed during the study period. | 3 days before the beginning of the administration to 48 hours after the end of the administration. |
| Respiratory rate | The respiratory status of all subjects will be recorded the incidence of abnormalities will be calculated. | 3 days before the beginning of the administration to 48 hours after the end of the administration. |
| Body temperature | The subjects' temperatures will be recorded and the abnormalities will be analyzed. | 3 days before the beginning of the administration to 48 hours after the end of the administration. |
| Peking University First Hospital |
| Principal Investigator |
| Xin Hu | Beijing Hospital | Principal Investigator |
| D000075224 |
| Cardiac Conduction System Disease |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |